Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Established in 2010 and headquartered in Los Angeles, California, the company concentrates its efforts on oncology drug candidates that address critical unmet medical needs. Puma engineers targeted small-molecule inhibitors designed to interfere with key pathways in tumor growth and proliferation, leveraging translational research to advance molecules from early discovery through clinical trials.
The company’s flagship product is Nerlynx (neratinib), an oral, irreversible tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive early stage breast cancer. Since receiving initial approval in 2017, Nerlynx has been adopted in multiple markets worldwide and has become a central component of Puma’s commercial activities. Beyond Nerlynx, Puma maintains a pipeline of novel compounds, including PB272 for the treatment of hormone receptor–positive breast cancer and PB357, a next-generation inhibitor targeting HER pathways in solid tumors.
Puma Biotechnology operates primarily in North America and Europe, partnering with leading pharmaceutical companies to maximize global reach. In Europe and select international territories, strategic alliances provide regulatory expertise and local marketing infrastructure, enabling broader patient access. The company’s clinical trial programs span multiple geographies, with ongoing studies conducted in the United States, Canada, Europe, and Asia to evaluate the safety and efficacy of pipeline candidates across diverse patient populations.
Leadership at Puma Biotechnology is spearheaded by Alan H. Auerbach, founder, chairman, and chief executive officer, whose background in pharmaceutical licensing and business development has shaped the company’s strategic direction. Under Auerbach’s guidance, Puma has cultivated a lean organizational structure that emphasizes scientific rigor and operational efficiency. The company’s management team includes seasoned professionals in clinical development, regulatory affairs, and commercial operations, all working in concert to advance Puma’s mission of bringing life-extending cancer therapies to patients worldwide.
AI Generated. May Contain Errors.
Free PBYI Stock Alerts